Klinická farmakologie a farmacie – 2/2021

www.klinickafarmakologie.cz / Klin Farmakol Farm 2021; 35(2): 88–93 / KLINICKÁ FARMAKOLOGIE A FARMACIE 93 PŘEHLEDOVÉ ČLÁNKY Orálne prejavy farmakologickej liečby systémových ochorení rozhodol, či v liečbe pokračovať, alebo liečbu radšej ukončiť (35). Veľkú väčšinu pacientov s MRONJ možno liečiť konzervatívnym spôso- bom, t. j. optimálna ústna hygiena, pravidelná profesionálna zubná starostlivosť, odstráne- nie aktívneho dentálneho a periodontálneho ochorenia, lokálne výplachy a systémová anti- biotická liečba. V pokročilom štádiu ochorenia sú indikované chirurgické výkony s osteotó- miou postihnutej oblasti. Záver V starnúcej populácii sa neustále zvyšuje počet predpísaných liekov na liečbu systé- mových ochorení, čo vedie aj k častejšiemu výskytu orálnych nežiaducich účinkov. Tieto prejavy sa môžu tiež zamieňať s nástupom nového ochorenia, čo spôsobí oddialenie kau- zálnej liečby s možným vznikom závažných komplikácií. Súčasťou každého stomatologic- kého vyšetrenia pacienta by preto malo byť aj zistenie liekovej anamnézy a úvaha o mož- nej súvislosti medzi užívanými medikament- mi a prejavmi v ústnej dutine. Pre správnu diagnostiku týchto nežiaducich prejavov je okrem podrobnej anamnézy a klinického vyšetrenia potrebná aj efektívna spolupráca s inými lekárskymi odbormi. Spracované s podporou grantu VEGA 1/0559/18. LITERATÚRA 1. Edwards D, Boritz E, Cowen EW, Brown RS. Erythema multi­ forme major following treatment with infliximab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115: e36–e40. 2. Yuan A, Woo SB. Adverse Drug Events in the Oral Cavity. Dermatol Clin. 2020; 38(4): 523–533. 3. Choi JH, Kim MJ, Kho HS. Oral Health-Related Quality of Life and Associated Factors in Patients with Xerostomia. Int J Dent Hyg. 2021 doi: 10.1111/idh.12528. Epub ahead of print. 4. Atif S, Syed SA, Sherazi UR, Rana S. Determining the relati- onship among stress, xerostomia, salivary flow rate, and the quality of life of undergraduate dental students. J Taibah Univ Med Sci. 2020; 16(1): 9–15. 5. Agha-Hosseini F, Moosavi MS, Mirzaii-Dizgah I, Samami M. Muscarinic cholinergic receptors in minor salivary gland tis- sues of patients with oral lichen planus: A case-control stu- dy. J Oral Pathol Med. 2020; 49(8): 816–821. 6. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003; 9(4): 165–176. 7. López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic Drugs in Geriatric Psychopharmacology. Front Neurosci. 2019; 13: 1309. 8. Van der Waal I. Oral lichen planus and oral lichenoid le- sions; A critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal. 2009; 14: E310–E314. 9. Ferrisse TM, de Oliveira AB, Palaçon MP, da Silveira HA, Mas- sucato EMS, de Almeida LY, Léon JE, Bufalino A. Immunohisto- chemical evaluation of Langerhans cells in oral lichen planus and oral lichenoid lesions. Arch Oral Biol. 2021; 124: 105027. 10. Sontheimer RD. Lichenoid tissue reaction/interface der- matitis: clinical and histological perspectives. J Invest Der- matol. 2009; 129(5): 1088–1099. 11. Lage D, Pimentel VN, Soares TC, Souza EM, Metze K, Cin- tra ML. Perforin and granzyme B expression in oral and cuta- neous lichen planus 1 a comparative study. J Cutan Pathol. 2011; 38(12): 973–978. 12. Lage D, Juliano PB, Metze K, de Souza EM, Cintra ML. Lichen planus and lichenoid drug-induced eruption: a his- tological and immunohistochemical study. Int J Dermatol. 2012; 51(10): 1199–1205. 13. Van der Meij EH, Mast H, van der Waal I. The possible pre- malignant character of oral lichen planus and oral lichenoid lesions: A prospective five-year follow-up study of 192 pati- ents. Oral Oncol. 2007; 43: 742–748. 14. Chiang CP, Yu-Fong Chang J, Wang YP, Wu YH, Lu SY, Sun A. Oral lichen planus – Differential diagnoses, serum autoanti- bodies, hematinic deficiencies, and management. J Formos Med Assoc. 2018; 117(9): 756–765. 15. Serrano-Sanchez P, Bagan JV, Soriano J, Sarrion G. Drug induced oral lichenoid reactions – A literature review. J Clin Exp Dent. 2010; 2: e71–e75. 16. Khammissa RAG, Chandran R, Masilana A, Lemmer J, Fel- ler L. Adverse Immunologically Mediated Oral Mucosal Re- actions to Systemic Medication: Lichenoid Tissue Reaction/ Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reacti- ons. J Immunol Res. 2018; 2018: 7645465. 17. Gawron K, Łazarz-Bartyzel K, Potempa J, Chomyszyn- -Gajewska M. Gingival bromatosis: Clinical,molecular and therapeutic issues. Orphanet J. Rare Dis. 2016; 11: 9. 18. Jayakaran TG. The effect of drugs in the oral cavity – A re- view. J Pharm Sci Res. 2014; 6: 89–96. 19. Dongari-Bagtzoglou, A. Informational paper: Drug-associa- ted gingival enlargement. J. Periodontol. 2004; 75: 1424–1431. 20. Mott ML, Bencivenni D, Cohen RE. Drug-induced gingi- val enlargement: An overview. Compend. Contin.Educ. Dent. 2013; 34: 330–336. 21. Seymour RA, Ellis JS, Thomason JM. Risk factors for dru- g-induced gingival overgrowth. J Clin Periodontol. 2000; 27(4): 217–223. 22. Vincent-Bugnas S, Borsa L, Gruss A, Lupi L. Prioritization of predisposing factors of gingival hyperplasia during ortho- dontic treatment: the role of amount of biofilm. BMC Oral Health. 2021; 21(1): 84. 23. Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119(1): 35–47. 24. Bakhtiari S, Sehatpour M, Mortazavi H, Bakhshi M. Orofa- cial manifestations of adverse drug reactions: a review stu- dy. Clujul Med. 2018; 91(1): 27–36. 25. Hatahira H, Abe J, Hane Y et al. Drug-induced gingival hy- perplasia: A retrospective study using spontaneous repor- ting system databases. J. Pharm. Health Care Sci. 2017; 3: 1–11. 26. Ruggiero SL, Dodson TB, Fantasia J et al. American Asso- ciation of Oral and Maxillofacial Surgeons. American Associ- ation of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10): 1938–1956. 27. Khan AA, Morrison A, Hanley DA et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and manage- ment of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30(1): 3–23. 28. Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. The Role of Platelet-Rich Fibrin (PRF) in the Preventi- on of Medication-Related Osteonecrosis of the Jaw (MRONJ). Biomed Res Int. 2021: 4948139. 29. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al. Incidence, risk factors, and outcomes of os- teonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012; 23: 1341–1347. 30. Savino S, Toscano A, Purgatorio R, Profilo E, Laghezza A, Tortorella P, Angelelli M, Cellamare S, Scala R, Tricarico D, Marobbio CMT, Perna F, Vitale P, Agamennone M, Dimiccoli V, Tolomeo A, Scilimati A. Novel bisphosphonates with anti- resorptive effect in bone mineralization and osteoclastoge- nesis. Eur J Med Chem. 2018; 158: 184–200. 31. de Oliveira CC, Brizeno LA, de Sousa FB, Mota MR, Alves AP. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) – Review. Med Oral Patol Oral Cir Bucal. 2016; 21(4): e431–e439. 32. Khan AA, Morrison A, Kendler DL et al. International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Os- teonecrosis of the Jaw (ONJ) and Application of the Interna- tional Recommendations for Management From the Inter- national Task Force on ONJ. J Clin Densitom. 2017; 20(1): 8–24. 33. Yoneda T, Hagino H, Sugimoto T et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017; 35(1): 6–19. 34. Yamazaki T, Yamori M, Ishizaki T et al. Increased inciden- ce of osteonecrosis of the jaw after tooth extraction in pati- ents treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012; 41: 1397. 35. Nicolatou-Galitis O, Schiødt M, Mendes et al. Medication- -related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(2): 117–135. 36. Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monza- ni F. Potential drug-drug interactions in Alzheimer pati- ents with behavioral symptoms. Clin Interv Aging. 2015; 10: 1457–1466. 37. Kamath VV, Setlur K, Yerlagudda K. Oral lichenoid lesi- ons – a review and update. Indian J Dermatol. 2015; 60(1): 102. 38. Brown RS, Arany PR. Mechanism of drug-induced gin- gival overgrowth revisited: a unifying hypothesis. Oral Dis. 2015; 21(1): e51–e61.